VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
1-Year Return
23.01%
This Quarter Return
+4.68%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$223M
AUM Growth
-$41.4M
(-16%)
Cap. Flow
-$33.4M
Cap. Flow
% of AUM
-14.95%
Top 10 Holdings %
Top 10 Hldgs %
11%
Holding
420
New
44
Increased
50
Reduced
231
Closed
47
Top Buys
| 1 |
The Mosaic Company
MOS
|
$2.75M |
| 2 |
STR
Sitio Royalties
STR
|
$2.32M |
| 3 |
Copel
ELP
|
$2.31M |
| 4 |
Vale
VALE
|
$2.26M |
| 5 |
Nutrien
NTR
|
$2.24M |
Top Sells
| 1 |
Boise Cascade
BCC
|
$2.62M |
| 2 |
Extra Space Storage
EXR
|
$2.49M |
| 3 |
Canadian Natural Resources
CNQ
|
$2.46M |
| 4 |
Imperial Oil
IMO
|
$2.45M |
| 5 |
Avient
AVNT
|
$2.42M |
Sector Composition
| 1 | Materials | 20.16% |
| 2 | Real Estate | 20.02% |
| 3 | Healthcare | 16.51% |
| 4 | Energy | 10.55% |
| 5 | Utilities | 10.47% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
301
Aldeyra Therapeutics
ALDX
$334M
| $102K | 0.05% |
22,945
-1,353
| -6% | -$6.02K |
|
302
uniQure
QURE
$981M
| $100K | 0.04% |
5,513
-328
| -6% | -$5.95K |
|
303
Zentalis Pharmaceuticals
ZNTL
$126M
| $100K | 0.04% |
2,169
-136
| -6% | -$6.27K |
|
304
Allogene Therapeutics
ALLO
$253M
| $99K | 0.04% |
10,848
-639
| -6% | -$5.83K |
|
305
Erasca
ERAS
$443M
| $99K | 0.04% |
11,532
-681
| -6% | -$5.85K |
|
306
Intellia Therapeutics
NTLA
$1.27B
| $98K | 0.04% |
1,353
-72
| -5% | -$5.22K |
|
307
Viking Therapeutics
VKTX
$2.97B
| $98K | 0.04% |
32,708
-1,945
| -6% | -$5.83K |
|
308
Invivyd
IVVD
$216M
| $97K | 0.04% |
21,355
-1,270
| -6% | -$5.77K |
|
309
Verastem
VSTM
$683M
| $97K | 0.04% |
5,744
-340
| -6% | -$5.74K |
|
310
Replimune Group
REPL
$477M
| $96K | 0.04% |
5,647
-339
| -6% | -$5.76K |
|
311
TG Therapeutics
TGTX
$4.99B
| $95K | 0.04% |
9,941
-595
| -6% | -$5.69K |
|
312
Instil Bio
TIL
$214M
| $95K | 0.04% |
441
-25
| -5% | -$5.39K |
|
313
Inovio Pharmaceuticals
INO
$146M
| $94K | 0.04% |
2,187
-129
| -6% | -$5.55K |
|
314
Precigen
PGEN
$1.35B
| $93K | 0.04% |
43,928
-2,603
| -6% | -$5.51K |
|
315
Atara Biotherapeutics
ATRA
$88.8M
| $92K | 0.04% |
395
-23
| -6% | -$5.36K |
|
316
Roivant Sciences
ROIV
$8.81B
| $92K | 0.04% |
18,546
-1,102
| -6% | -$5.47K |
|
|
MRTX
317
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $92K | 0.04% |
1,114
-69
| -6% | -$5.7K |
|
|
ADAP
318
Adaptimmune Therapeutics
ADAP
$12.7M
| $91K | 0.04% |
44,300
-2,631
| -6% | -$5.41K |
|
319
Prelude Therapeutics
PRLD
$65.1M
| $90K | 0.04% |
13,048
-767
| -6% | -$5.29K |
|
320
Day One Biopharmaceuticals
DAWN
$765M
| $88K | 0.04% |
8,886
-527
| -6% | -$5.22K |
|
321
Sutro Biopharma
STRO
$92.4M
| $88K | 0.04% |
10,670
-635
| -6% | -$5.24K |
|
|
INBX
322
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $88K | 0.04% |
3,968
-232
| -6% | -$5.15K |
|
323
Praxis Precision Medicines
PRAX
$988M
| $87K | 0.04% |
568
-34
| -6% | -$5.21K |
|
324
Vir Biotechnology
VIR
$725M
| $87K | 0.04% |
3,374
-194
| -5% | -$5K |
|
|
AMTI
325
DELISTED
Applied Molecular Transport Inc. Common Stock
AMTI
| $87K | 0.04% |
11,621
-692
| -6% | -$5.18K |
|